New scan could predict chemotherapy success in stomach cancer
NCT ID NCT04560036
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a special type of PET/MRI scan, using a tracer called FAZA, can measure low oxygen levels (hypoxia) in tumors of patients with metastasized gastro-oesophageal cancer. The goal is to see if this scan can predict how well patients will respond to standard chemotherapy. Forty adults with this cancer will get two scans—one before and one after chemotherapy—but the results won't change their treatment plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FAZA (a radioactive tracer used in PET/MRI scans)
- What this could lead to
- If successful, this could lead to a way to predict which patients will respond to chemotherapy, helping doctors choose more effective treatments.
- What could go wrong
- This is a small, early pilot study with only 40 participants. The scan results will not change treatment, so it is purely exploratory and may not lead to a usable test.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTASIZED GASTRO-OESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Univeristy Health Network
RECRUITINGToronto, Ontario, M5G 2N2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.